A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects

NCT05388903 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Netherton Syndrome

Interventions

DRUG: DS-2325a
DRUG: DS-2325a
DRUG: Placebo
DRUG: Placebo

Sponsor

Daiichi Sankyo